All In Biotech

Drug Trial Radar · NCT04014023

Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

196

Planned (sponsor's estimate)

Start

Jul 10, 2019

Primary completion

Mar 2020

Study completion Jun 2020

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • DWP16001Drug

    DWP16001 tablets

  • PlaceboDrug

    DWP16001 placebo-matching tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HbA1cTime frame: at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Daewoong pharmatceutical

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.